# US 2024/0197911 A1 · Oral Pharmaceutical Composition, Method for Fabricating Thereof, and Kit for Treating Cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0197911 A1
- Document ID: US20240197911A1
- Status: Published application
- Kind: A1
- Application number: 18/124,129
- Filed: 2023-03-21
- Published: 2024-06-20
- Earliest claimed: 2022-12-08
- Assignees: National Tsing Hua University
- Applicants: National Tsing Hua University
- Inventors: Hsing-Wen Sung; Kuan-Hung Chen; Tun-Yu Huang; Nhien Hoang To Nguyen; Yu-Jung Lin; Yu-Tzu Yu
- Web page: https://patentgrep.com/patent/US20240197911A1

## CPC

- A61K 47/6949: {inclusion complexes, e.g. clathrates, cavitates or fullerenes}
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 9/5115: {Inorganic compounds}
- A61K 9/5161: {Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin}
- A61K 31/12: Ketones
- A61K 31/203: Retinoic acids {; Salts thereof}
- A61K 31/352: condensed with carbocyclic rings, e.g. methantheline {(cannabinoids A61K31/658)}
- A61K 31/44: Non condensed pyridines; Hydrogenated derivatives thereof
- A61K 31/704: attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin {(digitoxin A61K31/7048)}
- A61K 39/39541: {against normal tissues, cells}
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61P 35/00: Antineoplastic agents
- C07K 16/2818: {against CD28 or CD152}
- A61K 2039/505: {comprising antibodies}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

An oral pharmaceutical composition includes a metal complex and an outer layer. The metal complex is formed by coordinate bonding of an organic compound to a metal ion, and the organic compound is an aromatic compound and includes at least two oxygen atoms. The outer layer includes a β-glucan, and the β-glucan is dispersed outside the metal complex and coordinately bonded to the metal complex to form the outer layer.

## Claims

### Claim 1

An oral pharmaceutical composition, comprising:
a metal complex formed by coordinate bonding of an organic compound to a metal ion, wherein the organic compound is an aromatic compound and comprises at least two oxygen atoms; and
an outer layer comprising a β-glucan, wherein the β-glucan is dispersed outside the metal complex and coordinately bonded to the metal complex to form the outer layer.

### Claim 2 (depends on 1)

The oral pharmaceutical composition of claim 1, wherein the oral pharmaceutical composition is a sphere, and the average particle size of the sphere is greater than or equal to 80 nm and less than 1 μm.

### Claim 3 (depends on 1)

The oral pharmaceutical composition of claim 1, wherein the metal ion is zinc ion (Zn2+), manganese ion (Mn2+), cobalt ion (Co2+), iron ion (Fe3+) or nickel ion (Ni2+).

### Claim 4 (depends on 1)

The oral pharmaceutical composition of claim 1, wherein the organic compound is doxorubicin (DOX), retinoic acid, curcumin, quercetin or sorafenib.

### Claim 5

A method for fabricating an oral pharmaceutical composition, comprising:
providing a mixed solution, wherein the mixed solution comprises an organic compound, a metal ion and a B-glucan, and the organic compound is an aromatic compound and comprises at least two oxygen atoms; and
performing a synthesis step, wherein energy is provided to the mixed solution, then the organic compound coordinates with the metal ion to form a metal complex, and the β-glucan coordinates with the metal complex to form the oral pharmaceutical composition.

### Claim 6 (depends on 5)

The method for fabricating the oral pharmaceutical composition of claim 5, wherein a molar ratio of the organic compound and the metal ion in the mixed solution is 0.5:1 to 8:1.

### Claim 7 (depends on 5)

The method for fabricating the oral pharmaceutical composition of claim 5, wherein the organic compound is doxorubicin (DOX), retinoic acid, curcumin, quercetin or sorafenib.

### Claim 8 (depends on 5)

The method for fabricating the oral pharmaceutical composition of claim 5, wherein the metal ion is formed by a dissociation of a metal salt in water, and the metal ion is zinc ion (Zn2+), manganese ion (Mn2+), cobalt ion (Co2+), iron ion (Fe3+) or nickel ion (Ni2+).

### Claim 9 (depends on 5)

The method for fabricating the oral pharmaceutical composition of claim 5, wherein in the synthesis step, energy is provided by a microwave or a heating.

### Claim 10 (depends on 4)

A kit for treating cancer, comprising:
the oral pharmaceutical composition of claim 4; and
a pharmaceutically acceptable carrier.

### Claim 11 (depends on 10)

The kit for treating cancer of claim 10, further comprising an immune checkpoint inhibitor.

### Claim 12 (depends on 11)

The kit for treating cancer of claim 11, wherein the immune checkpoint inhibitor is selected from the group consisting of PD-L1 antibody, PD-1 antibody, CTLA-4 antibody and TIM-3 antibody.
